Get the Stockscreener App
7.44
0.13%
0.01
Pre-market:
7.12
-0.32
-4.30%
Sage Therapeutics Inc stock is traded at $7.44, with a volume of 734.56K.
It is up +0.13% in the last 24 hours and down -8.15% over the past month.
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.
See More
Previous Close:
$7.43
Open:
$7.37
24h Volume:
734.56K
Relative Volume:
0.47
Market Cap:
$454.96M
Revenue:
$91.06M
Net Income/Loss:
$-503.14M
P/E Ratio:
-0.8868
EPS:
-8.39
Net Cash Flow:
$-424.74M
1W Performance:
+0.54%
1M Performance:
-8.15%
6M Performance:
-4.49%
1Y Performance:
-44.19%
1-Day Range:
$7.27
$7.64
1-Week Range:
$7.27
$7.64
52-Week Range:
$4.62
$14.97
Sage Therapeutics Inc Stock (SAGE) Company Profile
Name
Sage Therapeutics Inc
Sector
Industry
Phone
617-299-8380
Address
55 CAMBRIDGE PARKWAY, CAMBRIDGE, MA
Compare SAGE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SAGE
Sage Therapeutics Inc
|
7.44 | 454.96M | 91.06M | -503.14M | -424.74M | -8.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Sage Therapeutics Inc Stock (SAGE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-11-25 | Resumed | BofA Securities | Underperform |
| Nov-21-24 | Upgrade | RBC Capital Mkts | Underperform → Sector Perform |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Oct-04-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jul-30-24 | Downgrade | TD Cowen | Buy → Hold |
| Jul-25-24 | Downgrade | JP Morgan | Overweight → Neutral |
| May-29-24 | Initiated | Citigroup | Sell |
| May-29-24 | Initiated | Robert W. Baird | Neutral |
| Apr-17-24 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-12-23 | Initiated | Deutsche Bank | Hold |
| Aug-08-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Aug-08-23 | Downgrade | Goldman | Buy → Neutral |
| Aug-08-23 | Downgrade | Needham | Buy → Hold |
| Aug-07-23 | Downgrade | BofA Securities | Buy → Neutral |
| Aug-07-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-07-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-07-23 | Downgrade | Stifel | Buy → Hold |
| Aug-07-23 | Downgrade | Wedbush | Outperform → Neutral |
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Mar-13-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jan-03-23 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-01-22 | Initiated | Loop Capital | Hold |
| Mar-31-22 | Initiated | Berenberg | Hold |
| Nov-02-21 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-19-21 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-07-21 | Downgrade | Jefferies | Buy → Hold |
| Sep-23-21 | Initiated | Needham | Buy |
| Jun-16-21 | Downgrade | Citigroup | Buy → Neutral |
| Apr-07-21 | Initiated | Piper Sandler | Overweight |
| Feb-26-21 | Downgrade | Mizuho | Buy → Neutral |
| Feb-25-21 | Reiterated | H.C. Wainwright | Neutral |
| Feb-02-21 | Resumed | Raymond James | Mkt Perform |
| Jan-22-21 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jan-04-21 | Upgrade | Guggenheim | Neutral → Buy |
| Jan-04-21 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Dec-04-20 | Upgrade | Mizuho | Neutral → Buy |
| Dec-01-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-06-20 | Reiterated | H.C. Wainwright | Neutral |
| Sep-11-20 | Upgrade | Wedbush | Neutral → Outperform |
| Aug-10-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-08-20 | Downgrade | Wedbush | Outperform → Neutral |
| Apr-08-20 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-18-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-06-20 | Initiated | Citigroup | Buy |
| Feb-28-20 | Reiterated | H.C. Wainwright | Neutral |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-06-19 | Reiterated | RBC Capital Mkts | Outperform |
| Dec-05-19 | Reiterated | Guggenheim | Buy |
| Dec-05-19 | Downgrade | SunTrust | Buy → Hold |
| Oct-30-19 | Initiated | H.C. Wainwright | Neutral |
| May-23-19 | Initiated | Wedbush | Outperform |
| Apr-25-19 | Initiated | Jefferies | Buy |
| Dec-14-18 | Initiated | Wolfe Research | Outperform |
| Oct-11-18 | Initiated | Oppenheimer | Outperform |
View All
Sage Therapeutics Inc Stock (SAGE) Latest News
Sage Therapeutics (SAGE) Projected to Post Quarterly Earnings on Tuesday - Defense World
Sage Therapeutics, Inc. (NASDAQ:SAGE) Given Consensus Recommendation of “Hold” by Analysts - Defense World
Sage Therapeutics, Inc. (SAGE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - markets.businessinsider.com
Lobbying Update: $50,000 of SAGE THERAPEUTICS lobbying was just disclosed - Nasdaq
Q1 EPS Estimates for Sage Therapeutics Increased by Wedbush - Defense World
Q1 Earnings Forecast for SAGE Issued By Wedbush - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Sage Therapeutics, Inc. (SAGE) And Encourages Investors to Connect - markets.businessinsider.com
Bronstein, Gewirtz & Grossman, LLC Is Investigating Sage Therapeutics, Inc. (SAGE) And Encourages Stockholders to Connect - markets.businessinsider.com
Sage Therapeutics to Report First Quarter 2025 Financial Results on Tuesday, April 29, 2025 - BioSpace
Sage Therapeutics to Report First Quarter 2025 Financial Results on Tuesday, April 29, 2025 | SAGE Stock News - GuruFocus
Corebridge Financial Inc. Sells 2,050 Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) - Defense World
Sage Therapeutics, Inc. (NASDAQ:SAGE) Shares Sold by Vanguard Group Inc. - Defense World
Sage Therapeutics, Inc. (SAGE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Sage Therapeutics, Inc. (NASDAQ:SAGE) Position Lessened by American Century Companies Inc. - Defense World
KLP Kapitalforvaltning AS Buys New Position in Sage Therapeutics, Inc. (NASDAQ:SAGE) - Defense World
SAGE THERAPEUTICS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sage Therapeutics, Inc.SAGE - Business Wire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sage Therapeutics, Inc. (SAGE) and Encourages Stockholders to Learn More About the Investigation - markets.businessinsider.com
SAGE SHAREHOLDER ALERT: Kaskela Law LLC Announces - GlobeNewswire
SAGE SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Sage Therapeutics, Inc. - Bluefield Daily Telegraph
Sage Therapeutics: A Speculative Play That Needs To Wait For A Turnaround Story - Seeking Alpha
Sage Therapeutics: Biogen's $7.22/Share Bid Might Say More Than The Price Tag - Seeking Alpha
Class Action Filed Against Sage Therapeutics, Inc. (SAGE)October 28, 2024 Deadline to JoinContact Levi & Korsinsky - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Sage Therapeutics, Inc. (SAGE) Investors to Inquire about Securities Investigation - markets.businessinsider.com
(SAGE) Proactive Strategies - news.stocktradersdaily.com
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sage Therapeutics, Inc. (SAGE) And Encourages Investors to Reach Out - markets.businessinsider.com
Sage Therapeutics, Inc. (NASDAQ:SAGE) Shares Purchased by Thrivent Financial for Lutherans - Defense World
Sage Therapeutics, Inc. (SAGE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - markets.businessinsider.com
RBC Raises Price Target on SAGE Therapeutics to $7 From $6, Keeps Sector Perform, Speculative Risk - MarketScreener
Sage Therapeutics, Inc. (NASDAQ:SAGE) Shares Purchased by Teacher Retirement System of Texas - Defense World
SAGE LAWSUIT ALERT: Levi & Korsinsky Notifies Sage Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Sage Therapeutics, Inc. (SAGE) Shareholders to Inquire about Securities Investigation - markets.businessinsider.com
Bronstein, Gewirtz & Grossman, LLC Is Investigating Sage Therapeutics, Inc. (SAGE) And Encourages Shareholders to Connect - markets.businessinsider.com
Sage Therapeutics, Inc. (NASDAQ:SAGE) Shares Acquired by Charles Schwab Investment Management Inc. - Defense World
SAGE THERAPEUTICS INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sage Therapeutics, Inc.SAGE - The Malaysian Reserve
Sage Therapeutics, Inc. (NASDAQ:SAGE) Given Consensus Rating of “Hold” by Analysts - Defense World
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sage Therapeutics, Inc. (SAGE) And Encourages Shareholders to Reach Out - Markets Insider
Sage Therapeutics ($SAGE) Failed Drug Launch and Misleading FDA Guidance Case - TradingView
Status Epilepticus Market Statistics Expected to Experience Major Growth by 2032, According to DelveInsight | Marinus Pharma, Pfizer, UCB Biopharma SRL, Sage Therapeutics, Shire - The Globe and Mail
How To Trade (SAGE) - news.stocktradersdaily.com
Bank of New York Mellon Corp Has $931,000 Holdings in Sage Therapeutics, Inc. (NASDAQ:SAGE) - Defense World
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sage Therapeutics, Inc. (SAGE) and Encourages Investors to Learn More About the Investigation - Markets Insider
Amundi Invests $166,000 in Sage Therapeutics, Inc. (NASDAQ:SAGE) - Defense World
Investors who hold shares of Sage Therapeutics, Inc. (NASDAQ: - openPR.com
US Bancorp DE Acquires 2,268 Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) - Defense World
Notice to Long-Term Shareholders of Fluence Energy, Inc. - GlobeNewswire
Sage moved to Underperform at BofA; says Biogen’s buyout impact has passed - MSN
Attention Long-Term Shareholders of Driven Brands Holdings, Inc. (NASDAQ: DRVN); Mercury Systems, Inc. (NASDAQ: MRCY); Playstudios, Inc. (NASDAQ: MYPS); and Sage Therapeutics, Inc. (NASDAQ: SAGE): Grabar Law Office Investigates Claims on You - The Globe and Mail
Notice to Long-Term Shareholders of Mercury Systems, Inc. - GlobeNewswire
Notice to Long-Term Shareholders of Mercury Systems, Inc. (NASDAQ: MRCY); Methode Electronics, Inc. (NYSE: MEI); Monolithic Power Systems, Inc. (NASDAQ: MPWR); and Sage Therapeutics, Inc. (NASDAQ: SAGE): Grabar Law Office Investigates Claims - Morningstar
Notice to Long-Term Shareholders of Mercury Systems, Inc. (NASDAQ: MRCY); Methode Electronics, Inc. (NYSE: MEI); Monolithic Power Systems, Inc. (NASDAQ: MPWR); and Sage Therapeutics, Inc. (NASDAQ: SAGE): Grabar Law Office Investigates Claims on Your Behalf - GlobeNewswire Inc.
Sage Therapeutics Inc Stock (SAGE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.15%
4.32%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):